Análise de mutações nos genes TAC3 e TACR3 em pacientes com distúrbios puberais centrais idiopáticos
Mutational analysis of TAC3 and TACR3 genes in patients with idiopathic central pubertal disorders

Cintia Tusset¹, Sekoni D. Noel², Ericka B. Trarbach¹, Letícia F. G. Silveira¹, Alexander A. L. Jorge¹, Vinicius N. Brito¹, Priscila Cukier¹, Stephanie B. Seminara³, Berenice B. de Mendonça¹, Ursula B. Kaiser², Ana Claudia Latronico¹

ABSTRACT

Objective: To investigate the presence of variants in the TAC3 and TACR3 genes, which encode NKB and its receptor (NK3R), respectively, in a large cohort of patients with idiopathic central pubertal disorders. Subjects and methods: Two hundred and thirty seven patients were studied: 114 with central precocious puberty (CPP), 73 with normosmic isolated hypogonadotropic hypogonadism (IHH), and 50 with constitutional delay of growth and puberty (CDGP). The control group consisted of 150 Brazilian individuals with normal pubertal development. Genomic DNA was extracted from peripheral blood and the entire coding region of both TAC3 and TACR3 genes were amplified and automatically sequenced. Results: We identified one variant (p.A63P) in NKB and four variants, p.G18D, p.L58L (c.172C>T), p.W275* and p.A449S in NK3R, which were absent in the control group. The p.A63P variant was identified in a girl with CPP, and p.A449S in a girl with CDGP. The known p.G18D, p.L58L, and p.W275* variants were identified in three unrelated males with normosmic IHH. Conclusion: Rare variants in the TAC3 and TACR3 genes were identified in patients with central pubertal disorders. Loss-of-function variants of TACR3 were associated with the normosmic IHH phenotype.

Keywords
Neurokinin B; neurokinin B receptor; central precocious puberty; normosmic isolated hypogonadotropic hypogonadism; constitutional delay of growth and puberty
INTRODUCTION

Neurokinin B (NKB) is a member of the mammalian tachykinin family of peptides, classified as neurotransmitters that include substance P, neurokinin A, neurokinin B, as well as neuropeptide K, neuropeptide γ, and hemokinin-1 (1). Recent advances in the field of tachykinins have considerably increased interest in this peptide family (2). Anatomical, neurochemical, and pharmacological evidence suggest that these peptides could play a role as mediators of nonadrenergic and noncholinergic excitatory neurotransmission (3-5). Tachykinins interact with three distinct types of receptors termed NK1R, NK2R, and NK3R, which are preferentially activated by SP, NKA, and NKB, respectively (2). In humans, NKB and its receptor are encoded by the \( TAC3 \) and \( TACR3 \) genes, respectively (1,6).

The neurokinin B system has recently been implicated in the regulation of the human reproductive axis, following the identification of inactivating mutations in \( TAC3 \) and \( TACR3 \) genes in patients with normosmic isolated hypogonadotropic hypogonadism (IHH) (7). In a seminal study, Topaloglu and cols. (7) identified a critical role for NKB in human reproduction using genome-wide SNP analysis in nine inbred Turkish families with multiple members affected with normosmic IHH (7). In this study, rare missense variants in the \( TAC3 \) and \( TACR3 \) genes were described in four of these families with normosmic IHH (7). This first report implicated NKB signaling as an essential component for the onset of puberty and the control of gonadotropin secretion in humans (1). To date, approximately 50 individuals with \( TAC3 \) and \( TACR3 \) mutations have been described, with a worldwide distribution and a diverse racial mix (7-12). Recently, we reported that mutations in the NKB system occurred in more than 5% of a normosmic IHH population (10).

The mechanism whereby the NKB system exerts its effects on the central neuroendocrine control of human reproduction remains unknown (13). Several lines of evidence suggest that neurokinin B might have a role as a regulator of GnRH secretion (14). Furthermore, animal studies demonstrated that Kiss1 neurons of the arcuate nucleus coexpress NKB and dynorphin (Dyn) (14-16). These neurons were also confirmed to coexpress NK3R, suggesting a role in coordinating the activity of NKB/Dyn/Kisspeptin neurons of the arcuate nucleus.

Kisspeptin receptor and its ligand, kisspeptin, have been considered as major gatekeepers of puberty onset (17). Teles and cols. (18) reported a first activating mutation in the kisspeptin receptor (p.R386P) in an adopted Brazilian girl with central precocious puberty (18). More recently, Silveira and cols. (19) identified one new rare variant in the kisspeptin (p.P74S) in one boy with sporadic central precocious puberty. Therefore, it is also reasonable to hypothesize that gain-of-function mutation in \( TACR3 \), encoding a G protein-coupled receptor, might be identified in children with central precocious puberty (13). In this study, we investigated the presence of activating variants in the \( TAC3 \) and \( TACR3 \) genes in a large group of patients with idiopathic central precocious puberty. We also searched for inactivating variants in additional patients with normosmic IHH, as well as in patients with constitutional delay of growth and puberty.

MATERIALS AND METHODS

Patients

Two hundred and thirty seven patients with central pubertal disorders were studied: 114 with central precocious puberty (CPP), 73 with normosmic isolated hypogonadotropic hypogonadism (IHH), and 50 with constitutional delay of growth and puberty (CDGP) (Table 1). Sixty IHH patients were previously reported (10). All patients were evaluated at Universidade de Sao Paulo (USP), except 26 North American patients with CPP who were referred to Harvard Medical School. Informed written consent was obtained from all patients, and the study was approved by the Ethics Committee of the Hospital das Clinicas, Universidade de Sao Paulo. \( FGFR1, FGFR, GNRH1, GNRHR, KISS1R, KISS1, PROK2, \) and \( PROKR2 \) genes were previously studied in the cohort of patients with IHH. In addition, \( GNRHR, KISS1R, KISS1, \) and \( LIN28B \) genes were previously studied in Brazilian patients with CPP. The control population consisted of 150 healthy Brazilian individuals of both genders with normal pubertal development.

The diagnosis of central precocious puberty was based on the following criteria: puberty onset before eight years of age in girls and nine years of age in boys, pubertal LH levels (basal and/or after an acute GnRH stimulation test), and normal central nervous system magnetic resonance imaging (MRI).

The diagnosis of normosmic IHH was based on incomplete or absent pubertal development after 18 years, prepubertal or low testosterone or estradiol levels for the age, low or normal basal gonadotropin levels but...
Table 1. Clinical features at the time of diagnosis of the Brazilian patients with idiopathic central pubertal disorders

<table>
<thead>
<tr>
<th>Disorder</th>
<th>CPP</th>
<th>IHH</th>
<th>CDGP</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of patients</td>
<td>114</td>
<td>73</td>
<td>50</td>
</tr>
<tr>
<td>Gender</td>
<td>107 girls/7 boys</td>
<td>26 women/47 men</td>
<td>11 girls/39 boys</td>
</tr>
<tr>
<td>Chronological age</td>
<td>5.2 ± 2.1</td>
<td>23.8 ± 8.1</td>
<td>14.8 ± 1.4</td>
</tr>
<tr>
<td>Bone age</td>
<td>9.7 ± 2.5</td>
<td>14.5 ± 2.2</td>
<td>11.8 ± 1</td>
</tr>
<tr>
<td>Basal LH (IU/L)</td>
<td>1.5 ± 1.7</td>
<td>1.4 ± 2.1</td>
<td>1.0 ± 0.6</td>
</tr>
<tr>
<td>Peak LH (IU/L)</td>
<td>(not available)</td>
<td>(not available)</td>
<td>(not available)</td>
</tr>
<tr>
<td>FSH (IU/L)</td>
<td>17.9 ± 13.6</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Testosterone (ng/dL)¹</td>
<td>3.5 ± 1.9</td>
<td>1.9 ± 1.8</td>
<td>2.0 ± 1.1</td>
</tr>
<tr>
<td>Estradiol (pg/mL)²</td>
<td>280.0 ± 235.0</td>
<td>45.0 ± 33.0</td>
<td>65.0 ± 71.0</td>
</tr>
<tr>
<td>% Familial</td>
<td>19.4%¹</td>
<td>16.4%</td>
<td>22%</td>
</tr>
</tbody>
</table>

CPP: central precocious puberty; IHH: isolated hypogonadotropic hypogonadism; CDGP: constitutional delay of growth and puberty. The complete hormonal data were available for 76 Brazilian patients with CPP (72 girls and 4 boys), 59 patients with normosmic IHH (21 women and 38 men), and 50 patients with CDGP (11 girls and 39 boys).¹ Hormonal analyses of male patients.² Hormonal analyses of female patients. Peak LH: LH after acute GnRH stimulation test. IFMA (Immunofluorometric method). Reference ranges (IFMA): FSH (prepubertal girls and boys ≤ 3.2 IU/L; adult males 2.9-7.8 IU/L; adult females (follicular phase) 2.4-9.3 IU/L); LH (prepubertal girls and boys ≤ 0.6 IU/L; adult males 1.0-8.4 IU/L; adult females (follicular phase) 2.2-6.8 IU/L); Testosterone (prepubertal boys < 14 ng/dL; adult males 200-950 ng/dL); Estradiol (prepubertal girls < 21 pg/mL; adult females (follicular phase) 22-215 pg/mL). otherwise normal pituitary function, and normal hypothalamic-pituitary imaging. The diagnosis of CDGP was based on lack of breast development (Tanner stage 2) by the age of 13 and absent menarche by the age of 15 years in girls, and testicular volume < 4.0 mL by the age of 14 years in boys, absence of other identifiable causes of delayed puberty, delayed bone age, as well as spontaneous and complete achievement of pubertal development by age 18 years, during follow-up.

DNA analysis
Genomic DNA was extracted from peripheral blood leukocytes using standard procedures. The entire coding regions and the intron-exon junctions of TAC3 (GenBank accession number – MIM162330) and TACR3 (GenBank accession number – MIM162332) genes were amplified by polymerase chain reaction using specific primers, and were automatically sequenced (Table 2).

Amplification reactions were performed in a final volume of 25 µL containing 200 ng genomic DNA, 0.2 mM dNTPs, 1.5 mM PCRx Enhancer Solution (Invitrogen), 0.6 pmol each primer, 1X PCR buffer, and 1U Go Taq DNA polymerase (Promega, Madison, WI), and were carried out for 35 cycles: denaturation at 95°C for 30 s, annealing at 55-56°C for 30 s, extension at 72°C for 1 min, followed by a final extension for 10 min at 72°C. The PCR products were checked on 1% agarose gel electrophoresis, purified and automatically sequenced in an ABI Prism Genetic Analyzer 3100 automatic DNA sequencer (Applied Biosystems, Foster City, CA). All sequence variations were found on both strands and confirmed in a second PCR reaction.

In silico analyses
All mutations were analyzed using NNSPLICE 0.9 and Human Splice Finder to evaluate if these mutations could create or disrupt splice sites or auxiliary (enhancer or silencer) cis-splicing sequences. In addition, Polyphen-2 and SIFT were utilized to predict the potential impact of non-synonymous amino acid substitutions (missense variants) on protein structure and activity.

RESULTS
Central precocious puberty
Sequencing of the TAC3 gene revealed a heterozygous G to C transition in coding nucleotide 187 (c.187G>C) in a Brazilian girl with CPP. This mutation resulted in the substitution of alanine to proline at position 63 (p.A63P) of proneurokinin B (Table 3). The
The p.A63P variant was absent in the control population of 150 Brazilian patients. *In silico* analyses suggested that this variant does not alter the splicing sites, but it was predicted to be damaging to the protein (SIFT). However, the pathogenicity of this missense variant was not supported using the Polyphen-2 tool.

The affected girl had pubertal onset at 7 years of age. She had advanced bone age (11 years) and breast development pubertal stage Tanner 3. Hormonal evaluation revealed pubertal basal LH level (IFMA) of 1.2 U/L, LH after acute GnRH stimulation (IFMA) of 17.9 U/L, and pubertal basal estrogen level (IFMA) of 35.2 pg/mL. This girl was the only child of nonconsanguineous parents, and segregation analysis revealed that her mother, who had normal pubertal development with menarche at age 12, was also heterozygous for the p.A63P variant, and that her father was homozygous for the wild-type allele.

### Normosmic hypogonadotropic hypogonadism

Analysis of NK3R revealed three known distinct variants p.G18D, p.L58L (c.172C>T) and p.W275* in three unrelated males with normosmic IHH (Table 3). All of them were found in heterozygous state, except p.W275*, which was identified in the homozygous state in one IHH patient, and in the heterozygous state in association with the p.L58L (c.172C>T) variant in another. All variants affected highly conserved residues, and were absent in the control group.

The p.G18D variant was identified in a 24-year-old male. Physical examination showed micropenis, right and left testes < 2.5 cm, and pubic hair Tanner stage II. Hormonal evaluation revealed low basal gonadotropin (IFMA) (LH: 0.8 U/L; FSH: 1.4 U/L), and testosterone (IFMA) (< 19 ng/dL) levels. *In silico* analyses predicted an impact of the p.G18D substitution on protein structure using both PolyPhen and SIFT. Functional analysis of this variant demonstrated the NKB-stimulated fold increases in IP accumulation for WT and G18D NK3R were not significantly different (10).

The p.L58L (c.172C>T) and p.W275* variants were identified in a 20-year-old male. Physical examination showed right testes of 3.0 x 0.5 cm and left testes of 2.0 x 1.0 cm, and pubic hair Tanner stage III. Hormonal evaluation revealed low gonadotropins (RIA) (LH: 5 U/L; FSH: 9 U/L) and testosterone levels (RIA) (67 ng/dL). Similar cases of absent sexual development in his family were mentioned, but the affected family members were not available for genetic analysis.

Finally, the p.W275* variant in the homozygous state was identified in a 30-year-old male. Physical examination showed micropenis, right and left testes < 2.0 x 1.5 cm, and pubic hair Tanner stage III. Hormonal evaluation revealed low basal gonadotropin (IFMA) (LH: < 0.6 U/L; FSH: < 1.0 U/L) and testosterone (IFMA) (35 ng/dL) levels. Familial segregation was not available. The mean (±SD) FSH/LH ratio of the three IHH patients with TACR3 variants was 2.40 ± 1.33.

### Constitutional delay of growth and puberty

A new heterozygous variant in the TACR3 gene (c.1345G>T) was identified in a girl with CDGP. This variant resulted in the substitution of alanine to serine at position 449 (p.A449S) of NK3R (Table 3). The p.A449S variant was not identified in any subjects of the control group. Alanine at position 449 is not a conserved residue among all species, and *in silico* analysis suggested that this variant neither altered a splicing site nor was deleterious to protein structure or function.

The affected girl had pubertal onset at 13.4 years of age, and delayed bone age (11 years). Hormonal evaluation revealed a pre-pubertal basal LH level (IFMA) 0.6 U/L, and a low basal estrogen level (IFMA) 19 pg/mL. The affected patient reported similar cases in her family, but these relatives were not available for segregation analysis.

---

**Table 3.** Variants of *TAC3* and *TACR3* genes identified in patients with idiopathic central pubertal disorders

<table>
<thead>
<tr>
<th>Gene</th>
<th>Nucleotide change</th>
<th>Amino acid change</th>
<th>Status</th>
<th>Exon</th>
<th>Phenotype</th>
</tr>
</thead>
<tbody>
<tr>
<td>TAC3</td>
<td>c.187G&gt;C</td>
<td>p.A63P</td>
<td>Heterozygous</td>
<td>3</td>
<td>Sporadic CPP</td>
</tr>
<tr>
<td>TACR3</td>
<td>c.53G&gt;A</td>
<td>p.G18D</td>
<td>Heterozygous</td>
<td>1</td>
<td>Sporadic IHH</td>
</tr>
<tr>
<td></td>
<td>c.[172C&gt;T] 824G&gt;A</td>
<td>p.[L58L(W275*)]</td>
<td>Compound heterozygous</td>
<td>1 and 3</td>
<td>Familial IHH</td>
</tr>
<tr>
<td></td>
<td>c.824G&gt;A</td>
<td>p.W275*</td>
<td>Homozygous</td>
<td>3</td>
<td>Familial IHH</td>
</tr>
<tr>
<td></td>
<td>c.1345G&gt;T</td>
<td>p.A449S</td>
<td>Heterozygous</td>
<td>5</td>
<td>Familial CDGP</td>
</tr>
</tbody>
</table>

*p.A63P* variant was absent in the control population of 150 Brazilian patients. *In silico* analyses suggested that this variant does not alter the splicing sites, but it was predicted to be damaging to the protein (SIFT). However, the pathogenicity of this missense variant was not supported using the Polyphen-2 tool.

The affected girl had pubertal onset at 7 years of age. She had advanced bone age (11 years) and breast development pubertal stage Tanner 3. Hormonal evaluation revealed pubertal basal LH level (IFMA) of 1.2 U/L, LH after acute GnRH stimulation (IFMA) of 17.9 U/L, and pubertal basal estrogen level (IFMA) of 35.2 pg/mL. This girl was the only child of nonconsanguineous parents, and segregation analysis revealed that her mother, who had normal pubertal development with menarche at age 12, was also heterozygous for the p.A63P variant, and that her father was homozygous for the wild-type allele.

### Normosmic hypogonadotropic hypogonadism

Analysis of NK3R revealed three known distinct variants p.G18D, p.L58L (c.172C>T) and p.W275* in three unrelated males with normosmic IHH (Table 3). All of them were found in heterozygous state, except p.W275*, which was identified in the homozygous state in one IHH patient, and in the heterozygous state in association with the p.L58L (c.172C>T) variant in another. All variants affected highly conserved residues, and were absent in the control group.

The p.G18D variant was identified in a 24-year-old male. Physical examination showed micropenis, right and left testes < 2.5 cm, and pubic hair Tanner stage II. Hormonal evaluation revealed low basal gonadotropin (IFMA) (LH: 0.8 U/L; FSH: 1.4 U/L), and testosterone (IFMA) (< 19 ng/dL) levels. *In silico* analyses predicted an impact of the p.G18D substitution on protein structure using both PolyPhen and SIFT. Functional analysis of this variant demonstrated the NKB-stimulated fold increases in IP accumulation for WT and G18D NK3R were not significantly different (10).

The p.L58L (c.172C>T) and p.W275* variants were identified in a 20-year-old male. Physical examination showed right testes of 3.0 x 0.5 cm and left testes of 2.0 x 1.0 cm, and pubic hair Tanner stage III. Hormonal evaluation revealed low gonadotropins (RIA) (LH: 5 U/L; FSH: 9 U/L) and testosterone levels (RIA) (67 ng/dL). Similar cases of absent sexual development in his family were mentioned, but the affected family members were not available for genetic analysis.

Finally, the p.W275* variant in the homozygous state was identified in a 30-year-old male. Physical examination showed micropenis, right and left testes < 2.0 x 1.5 cm, and pubic hair Tanner stage III. Hormonal evaluation revealed low basal gonadotropin (IFMA) (LH: < 0.6 U/L; FSH: < 1.0 U/L) and testosterone (IFMA) (35 ng/dL) levels. Familial segregation was not available. The mean (±SD) FSH/LH ratio of the three IHH patients with TACR3 variants was 2.40 ± 1.33.

### Constitutional delay of growth and puberty

A new heterozygous variant in the TACR3 gene (c.1345G>T) was identified in a girl with CDGP. This variant resulted in the substitution of alanine to serine at position 449 (p.A449S) of NK3R (Table 3). The p.A449S variant was not identified in any subjects of the control group. Alanine at position 449 is not a conserved residue among all species, and *in silico* analysis suggested that this variant neither altered a splicing site nor was deleterious to protein structure or function.

The affected girl had pubertal onset at 13.4 years of age, and delayed bone age (11 years). Hormonal evaluation revealed a pre-pubertal basal LH level (IFMA) 0.6 U/L, and a low basal estrogen level (IFMA) 19 pg/mL. The affected patient reported similar cases in her family, but these relatives were not available for segregation analysis.
**NK3R SNPS**

Three polymorphisms previously described in the NK3R were identified in this cohort of patients. The p.K286R (c.857A>G) variant was identified in 0.9%, 1.4%, and 2% of patients with CPP, normosmic IHH and CDGP, respectively, and it was not found in any control individual studied. The p.L291L (c.873A>G) variant was identified in 2.6%, 1.4% and 4% of patients with CPP, normosmic IHH and CDGP, respectively, and it was found in 4% of control individuals studied. The p.A449T (c.1345G>A) variant was identified in 1.4% and 4% of patients with normosmic IHH and CDGP, respectively, and in 1% of control individuals studied. Polymorphism frequencies were similar to those previously reported.

**DISCUSSION**

Complex networks of inhibitory, stimulatory and permissive neuroendocrine factors are involved in the control of puberty onset. Loss-of-function mutations in the TAC3 and TACR3 genes result in normosomic IHH, characterized by an absence of pubertal development and low circulating levels of LH and gonadal steroids (7-12). A recent study identified rare variants in genes associated with IHH in women with hypothalamic amenorrhea, suggesting that these mutations may also contribute to the variable susceptibility of women to functional changes in GnRH secretion (21). These observations provided compelling evidence for the role of rare variants in common multifactorial diseases. In this study, we analyzed the TAC3 and TACR3 genes in a cohort of patients with central pubertal disorders, including patients with central precocious puberty, normosmic IHH, and constitutional delay of growth and puberty. We described five variants, one in NKB (p.A63P) and four in NK3R (p.G18D, p.L58L, p.W275* and p.A449S) in five unrelated patients with central pubertal disorders. All of these variants were absent in the control group, suggesting that they are not common polymorphisms in the Brazilian population.

Activating mutations in KISS1 and KISS1R, a G protein-coupled receptor, were previously identified in Brazilian girls with CPP (18,19). Indeed, it is known that NKB is highly expressed in hypothalamic neurons that also express kisspeptin, and that NKB/NK3R are involved in the regulation of pubertal development (14). Hence, it is also reasonable to hypothesize that gain-of-function mutations in NKB or in NK3R, another G protein-coupled receptor, might be identified in children with CPP. In this study, a new heterozygous variant (p.A63P) in proneurokinin B was identified in a Brazilian girl with central precocious puberty who had pubertal onset at 7 years of age. TAC3 precursor mRNA contains seven exons, five of which are translated to form the preprotachykinin B peptide. This prepropeptide undergoes enzymatic cleavage to form proproneurokinin B, then NKB. Loss-of-function mutations in propeptides have been described in association with several phenotypes (22-24). Activating mutations in propeptides are rare, and no functional studies identifying gain-of-function mutations in propeptides have been described to date. Comparative analysis of the amino acid sequence of neurokinin B showed that the alanine in position 63 is a conserved residue among primates. Nonetheless, this variant was not predicted to alter the splicing site, and the functional effects of this amino acid substitution were controversial using different in silico algorithms.

Recent studies of humans with TAC3 and TACR3 inactivating mutations provide compelling evidence for the involvement of neurokinin B signaling in human puberty (7-12). In this study, we identified three distinct variants (p.G18D, p.L58L and p.W275*) in NK3R in three unrelated males with IHH who were previously described (10). All of them were heterozygous, except for p.W275*. The p.W275* variant was the most prevalent variant identified in the TACR3 gene in this Brazilian cohort of patients, as well in the Gianetti and cols. (10) multicenter cohort. Furthermore, heterozygous variants were found in two of three patients with TACR3 variants. Based on these findings, it is possible that our screening strategy failed to identify mutations in other regions. It is also possible that the heterozygous mutations in TACR3 do not contribute to the pathogenesis of normosmic IHH, and that only the homozygous mutations have a causative role in IHH. Nevertheless, there are clear precedents for the association of normosmic IHH and Kallmann syndrome with heterozygous mutations in FGFR8 and PROK2, which also encode secreted ligands (25-28). Another possibility is that heterozygous TACR3 mutations act in conjunction with mutations in other genes to cause normosomic IHH, a mechanism previously described in normosomic IHH and Kallmann syndrome (25,29-31).

A high frequency of micropenis was detected in patients with TAC3/TACR3 variants, indicating NKB/
NK3R signaling may be essential for the normal activation of the reproductive axis late in gestation (7,10-12). All IHH patients with TACR3 variants were in the second decade of life or older, and showed unequivocal evidence of failure of pubertal progression with low circulating sex steroids and prepubertal levels of circulating gonadotropins, and all of them presented with micropenis without cryptorchidism. Recently, dissociation between the very low basal LH and normal or nearly normal basal FSH levels was reported, suggesting the possibility of a specific neuroendocrine impairment and therefore impaired pulsatile delivery of GnRH in patients with alteration of NKB signaling (7,8,12). However, this hormonal profile was not observed in our study. IHH Brazilian patients with TACR3 variants showed similar FSH/LH ratios when compared to other IHH patients with mutations in GNRHR, KISS1R/ GNRHR1, KISS1R/PROKR2, PROKR2, FGR1, FGF8, and in IHH patients with no identified genetic variants (data not shown).

Comparative analyses of the amino acid sequences of NK3R showed that these substitutions affected highly conserved residues among all species. In silico analyses were performed, and they suggested that p.G18D variant could be damaging to protein structure, but in vitro studies revealed no significant differences in receptor signaling between wild type and mutant NK3R (10), suggesting that p.G18D variant is not responsible for the IHH phenotype.

Constitutional delay of growth and puberty is, at least in part, genetically determined. Although many genes may be involved with this condition, the inheritance patterns suggest that there are still-to-be-uncovered single genes with major effects (32-34). We hypothesized that mutations in genes underlying IHH might contribute for the pathogenesis of this condition, with incomplete penetrance and/or variable expressivity (33). Recently, mutations in TAC3 or TACR3 genes in patients with IHH have been associated with high frequency of reversal IHH, a phenotype resembling constitutional delay of growth and puberty (10). Although the NKB/NK3R complex appear to be clear functional candidates for CDGP, no mutations in the coding region of these system have been described in the literature (33).

In this study, we identified a new heterozygous variant (p.A449S) in NK3R in a Brazilian girl with CDGP who had breast development at 13.4 years of age. Comparative analysis of the amino acid sequence of NK3R showed that alanine at position 449 is not a conserved residue among species. In silico analyses suggested that this substitution did not alter splicing sites (NNSPLICE 0.9 and Human Splicing Finder), neither was damaging to the protein (PolyPhen and SIFT). Taken together, these data did not support a potential role for the p.A449S variant in the CDGP phenotype.

In conclusion, we described new rare variants in the NKB (p.A63P) and in the NK3R (p.A449S) in two girls, one with central precocious puberty and one with constitutional delay of growth and puberty. Our preliminary studies suggested that these two new variants do not seem to have a direct causative role in the precocious puberty and constitutional delay of growth and puberty phenotype. In addition, we identified three known distinct variants (p.G18D, p.L58L, and p.W275X) in the NK3R in three unrelated males with normosmic hypogonadotropic hypogonadism. Finally, we identified a positive association between TAC3 and TACR3 variants and a normosmic IHH phenotype, indicating that NKB signaling is required for initiation and normal pubertal development.

Acknowledgements: this study was supported by Fapesp grants 05/04726 and Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) grants 302825/2011-8 (to A.C.L.), by Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) grants 305743/2011-8 (to B.B.M.), and by the Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health (NIH), by means of the collaborative agreement U54 HD28138 as part of the Specialized Cooperative Centers Program in Reproduction and Infertility Research (to U.B.K.).

Disclosure: no potential conflict of interest relevant to this article was reported.

REFERENCES
5. Zagorodnyuk V, Maggi CA. Tachykinin NK1 and NK2 receptors mediate non-adrenergic non-cholinergic excitatory neurumus-


